Table 1. Overall survival (univariate and multivariate analysis) and patient characteristics.
| Characteristics | N=69 | Univariate | Multivariate |
|---|---|---|---|
| Sex | P=0.3 (0.4–1.3) | P=0.9 (0.5–2.0) | |
| Male | 37 (53.6%) | ||
| Female | 32 (46.4%) | ||
| Age ≥75 | P=0.2 (0.5–2.2) | P=0.09 (0.9–4.8) | |
| No | 59 (85.5%) | ||
| Yes | 10 (14.5%) | ||
| Dead | – | – | |
| Yes | 57 (82.6%) | ||
| No | 12 (17.4%) | ||
| Progressed | – | – | |
| Yes | 60 (87%) | ||
| No | 9 (13%) | ||
| TPS score | P=0.01 (0.2–0.9) | P=0.02 (0.2–0.9) | |
| ≤1% | 22 (31.9%) | ||
| 1–49% | 31 (44.9%) | ||
| ≥50% | 16 (23.2%) | ||
| Immunotherapy | P=0.8 (0.5–2.2) | P=0.3 (0.6–3.6) | |
| Pembrolizumab | 59 (85.5%) | ||
| Atezolizumab | 9 (13%) | ||
| Ipilimumab | 1 (1.15%) | ||
| Ipilimumab/Nivolumab | 1 (1.5%) | ||
| Line of therapy | P=0.03 (0.7–0.9) | P=0.04 (0.8–0.9) | |
| 1st Line | 32 (46.4%) | ||
| 2nd Line | 30 (43.5%) | ||
| 3rd Line | 5 (7.3%) | ||
| ICI + denosumab duration | P=0.001 (0.2–0.7) | P=0.0003 (0.09–0.4) | |
| <3 months | 49 (71%) | ||
| >3months | 20 (29%) | ||
| Radiation therapy | P=0.2 (0.4–1.2) | P=0.6 (0.6-2.1) | |
| Yes | 47 (68.1%) | ||
| No | 22 (21.9%) | ||
| Skeletal metastases | P=0.2 (0.8–2.3) | P=0.6 (0.5–2.8) | |
| <3 | 43 (62.3%) | ||
| >3 | 26 (37.7%) | ||
| Brain metastases | P=0.7 (0.6–1.9) | P=0.08 (0.9-4.2) | |
| Yes | 43 (62.3%) | ||
| No | 26 (37.7%) | ||
| Number of metastatic sites | P=0.3 (0.8–2.3) | P=0.2 (0.6–5.6) | |
| 1–3 sites | 28 (40.6%) | ||
| >3 sites | 41 (59.4%) | ||
| Hypocalcemia | – | – | |
| Yes | 26 (37.7%) | ||
| No | 63 (62.3%) | ||
| LDH | P=0.7 (0.5–2.2) | P=0.5 (0.3–1.7) | |
| >220 IU | 52 (81.3%) | ||
| <220 IU | 12 (18.7%) |
TPS, tumor proportion score; ICI, immune checkpoint inhibitors; LDH, lactate dehydrogenase.